The efficacy of chemotherapy in the patients with stage II colon cancer associated with number of high-risk factors
Korean Journal of Clinical Oncology 2018³â 14±Ç 2È£ p.116 ~ p.119
±è¹ÎÁÖ(Kim Min-Joo) - Pusan National University Hospital Department of Surgery
¹é½ÂÇö(Baek Seung-Hyun) - Pusan National University Hospital Department of Surgery
(Ko Sang-Hwa) - Busan Medical Center Department of Surgery
Abstract
Purpose: This study assessed the effect of chemotherapy over stage II colon cancer in terms of presence of high-risk factors.
Methods: Data were retrospectively reviewed for 364 patients with stage II colon cancer who underwent curative surgery between January 2007 and December 2012. High-risk factors of stage II colon cancer were examined, and the overall survival (OS) rates were analyzed. Survival benefit of adjuvant chemotherapy was also analyzed.
Results: One hundred and fifteen cases had exclusively single high-risk factor and 194 cases were negative for high-risk factors. Postoperative chemotherapy was performed in 262 of 364 patients (72.0%). The 5-year OS was 79.4% and 86.6% for patients without adjuvant chemotherapy and those with chemotherapy, respectively. The 5-year OS was 88.2% and 83.3% for patients having exclusively single high-risk factor with adjuvant chemotherapy and those without chemotherapy, respectively.
Conclusion: Adjuvant chemotherapy for patients with stage II colon cancer having exclusively single high-risk factor could be omitted, weighing up the survival benefit and side effect of chemotherapy.
Å°¿öµå
Colorectal neoplasms, Drug therapy, Survival analysis
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
This study highlights the lack of a significant survival benefit of adjuvant chemotherapy in patients having none or exclusively single high-risk factors of stage II colon cancer.